Corporate Information And Statement Of Ifrs Compliance [Abstract]

Carl Zeiss Meditec AG - Filing #6525304

Concept 2022-10-01 to
2023-09-30
As at
2023-09-30
As at
2022-09-30
Corporate information and statement of IFRS compliance [abstract]
Name of reporting entity or other means of identification
Carl Zeiss Meditec AG
Legal form of entity
Aktiengesellschaft
Country of incorporation
Deutschland
Address of entity's registered office
Göschwitzer Straße 51-52, 07745 Jena
Description of nature of entity's operations and principal activities
Die Gruppe bietet Komplettlösungen zur Diagnose und Behandlung von Augenkrankheiten einschließlich Implantaten  
Name of parent entity
Carl Zeiss AG
Name of ultimate parent of group
Carl-Zeiss-Stiftung
Disclosure of reclassifications or changes in presentation [text block]
29 Angaben
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Current inventories
520,228 EUR
382,745 EUR
Current trade payables
157,829 EUR
124,388 EUR
Explanation of sources of estimation uncertainty with significant risk of causing material adjustment
Gebrauch von Schätzungen  
Disclosure of objectives, policies and processes for managing capital [text block]
37 Zusätzliche
Dividends recognised as distributions to owners per share
110.00
Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners
98,385 EUR
Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share
110.00

Talk to a Data Expert

Have a question? We'll get back to you promptly.